

Who We Are

Foundation Medicine is a **genomics** company committed to **transforming cancer care**.

We develop high-quality diagnostic tests that accurately identify the genomic mutations driving a patient's cancer, match a patient to the most effective treatment options, including targeted therapies, immunotherapies or clinical trials, and monitor a patient's response to treatment. Harnessing our genomic expertise, we partner with leading research institutions, physicians, scientists and biopharmaceutical companies to fuel the next generation of scientific breakthroughs. Every day, we are driven by the pursuit of personalized answers for all patients living with cancer.

GLOBAL FOOTPRINT & FAST FACTS



~1,700
employees globally
(As of May 2024)



Headquartered in
Boston, Massachusetts
Additional laboratories in: Cambridge, Massachusetts, Morrisville, North Carolina, San Diego, California, and Penzberg, Germany



Our global reach includes partner labs in **Switzerland and China** to support clinical trials and partnership with Chugai Pharmaceutical Co., LTD. to commercialize tests in **Japan**



Tests available to patients
in all 50 U.S. states and 100+ countries



>1 million
patient reports
delivered to date



86% of patients have
\$0 financial responsibility for testing¹



Independent affiliate of
The Roche Group
(acquired in 2018)

Our High-Quality Genomic Testing Portfolio

IDENTIFYING POTENTIAL TREATMENT OPTIONS AND SUPPORTING RESEARCHERS

We are the only company to offer both tissue and blood-based comprehensive genomic profiling tests that are approved by the U.S. Food and Drug Administration. Our tests help physicians create personalized treatment plans and support researchers in uncovering new biomarkers.

	Product	Cancer Type	Biopsy Type
U.S. FOOD AND DRUG ADMINISTRATION APPROVED	FoundationOne®CDx	All Solid Tumors	Tissue-based Biopsy
	FoundationOne®Liquid CDx	All Solid Tumors	Blood-based Biopsy
NEW YORK STATE APPROVED	FoundationOne®Heme	Hematologic Malignancies & Sarcomas	Tissue-based Biopsy or Blood-based Biopsy
	FoundationOne®RNA ²	All Solid Tumors	Tissue-based Biopsy

MONITORING TREATMENT RESPONSE

Our circulating tumor DNA (ctDNA) monitoring test which is currently in development may help physicians and researchers identify patients who are resistant to their current treatment and may need a different therapy, or those who are responding well and need tailoring to their treatment plan.

Product	Cancer Type	Monitoring Type
FoundationOne®Monitor (Available for research and investigational use only)	All Solid Tumors	Tissue-naïve, tests blood only to monitor changes to ctDNA levels

Global Leader in Approved Companion Diagnostic Indications



Foundation Medicine is a leading companion diagnostics developer with nearly 60% of all approved companion diagnostic (CDx) indications for next generation sequencing testing across the United States and Japan^{3,4}.

Companion diagnostics are high-quality tests proven to accurately match a patient to a targeted therapy or immunotherapy⁵. They are approved by the U.S. Food and Drug Administration (FDA) based on clinical trials designed to demonstrate the patients who may or may not benefit from a particular drug.

UNITED STATES

(As of May 2024)

FoundationOne®CDx:
37 companion diagnostic indications including therapies from 3 group claims

FoundationOne®Liquid CDx:
12 companion diagnostic indications including therapies from 1 group claim

JAPAN

(As of May 2024)

FoundationOne®CDx:
30 companion diagnostic indications

FoundationOne®Liquid CDx:
12 companion diagnostic indications

Powering Scientific Breakthroughs

We are committed to pushing the boundaries of science with the goal of **delivering breakthroughs** that help more patients in the future. We **drive complex biomarker research** and discovery that guide the development of more precise treatment options. We **partner with biopharmaceutical organizations globally** to accelerate the development of new therapies by designing more efficient clinical trials and developing companion diagnostics. We are working to **demonstrate utility of our testing in earlier stages of disease** and to **advance our monitoring technology** to detect a patient's response to therapy through a simple blood draw.

OUR RESEARCH IMPACT



850+
clinical trials supported since 2012



800+
total peer reviewed publications since 2011



800K+
de-identified patient tumor samples available for research use via our FoundationCore database



In 2023, collaborated with **230+** cancer centers and research institutions to advance cancer research through clinical trials and publications



125K+ linked patient profiles available in the Flatiron Health-Foundation Medicine Clinico-Genomic Database (CGDB) enabling analysis of how genomic information impacts patient outcomes

Social and Environmental Responsibility Initiatives



Foundation Medicine is committed to **reducing our overall environmental impact** and investing in programs that bring **equity and inclusivity to our patients and employees**.

- Registered all new buildings with the **LEED® green building program** and are committed to **responsible sourcing of utilities and minimizing our waste stream**.
- Issued "Call for Grants Notification" and awarded \$100,000 to catalyze programs **focused on closing existing disparities in care** by increasing genomic testing education, awareness and access among underserved populations in the United States⁶.

Corporate Awards & Recognition

UNITED STATES

Boston Business Journal
Best Place to Work
2022, 2023

Newsweek, America's 100
Most Loved Workplaces
2023

San Diego Business Journal
Best Place to Work
2022, 2023

Triangle Business Journal
Best Place to Work
2022

GERMANY

kununu Top Company
2022, 2023, 2024

Top 100 Best Workplaces
2023, 2024

TOP 100 Innovator
in Germany
2022, 2023

References

- Data on File, Foundation Medicine, Inc., 2023. Based on US settled claims for FoundationOne®CDx, FoundationOne®Liquid CDx, FoundationOne®Heme, and PD-L1 IHC ordered from Foundation Medicine, reported between 1/1/22 and 3/31/23 before considering any financial assistance. 65% of commercially insured and 96% of Medicare and Medicare Advantage patients owe \$0 for Foundation Medicine testing.
- FoundationOne®RNA is conditionally approved by New York State's Clinical Laboratory Evaluation Program. <https://cfwww10-origin.wadsworth.org/regulatory/clep/approved-ltd>
- List of Cleared or Approved Companion Diagnostic Devices (In Vitro and Imaging Tools). <https://www.fda.gov/medical-devices/in-vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-in-vitro-and-imaging-tools>.
- List of Vitro Companion Diagnostics or Medical Devices (CDx Products) Approved in Japan. <https://www.pmda.go.jp/files/000264514.pdf>.
- In Vitro Companion Diagnostic Devices. Guidance for Industry and Food and Drug Administration Staff. <https://www.fda.gov/media/81309/download>.
- Foundation Medicine Awards Grant to Moffitt Cancer Center and LUNGeVity to Help Remove Barriers to Information About Personalized Oncology for Black Patients. <https://www.foundationmedicine.com/press-releases/cf895bda-9612-415a-9dd2-51e1b47d275a>.

FoundationOne®CDx and FoundationOne®Liquid CDx are next-generation sequencing based in vitro diagnostic tests for advanced cancer patients with solid tumors and are for prescription use only. They are companion diagnostics to identify patients who may benefit from treatment with specific therapies in accordance with the approved therapeutic product labeling. Additional genomic findings may be reported and are not prescriptive for labeled use of any specific therapeutic product. Use does not guarantee a match to treatment or that all relevant alterations will be found. For the complete labels please visit www.FILCDxLabel.com and www.FILCDxLabel.com.

FoundationOne®Heme, Laboratory Developed Test; Approved by New York State's Clinical Laboratory Evaluation Program; Prescription use only; advanced cancer; Use does not guarantee treatment match.

